Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TDP2 | O95551 | 1/20 | 0.56 |
| ▸ | NGF | P01138 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9635901 | 0.82 | MEN1 (0.61) | GSRMAPTMEN1KMT2ATDP2 | |
| SCHEMBL8336453 | 0.80 | MEN1 (0.52) | GSRMAPTMEN1KMT2ATDP2 | |
| SCHEMBL4748217 | 0.80 | TDP2 (0.62) | GSRMAPTMEN1KMT2ATDP2 | |
| SCHEMBL9635970 | 0.80 | HTT (0.54) | GSRMAPTMEN1KMT2AKDM4E | |
| SCHEMBL9635797 | 0.79 | GSR (0.70) | GSRMEN1KMT2ATDP2RECQL | |
| Lumiflavin SCHEMBL29516802 | 0.79 | MEN1 (0.76) | GSRMAPTMEN1KMT2ATDP2 | |
| Lumiflavin SCHEMBL193713 | 0.79 | MEN1 (0.76) | GSRMAPTMEN1KMT2ATDP2 | |
| SCHEMBL28727266 | 0.78 | TLR8 (0.54) | GSRMAPTKDM4EALDH1A1GAA | |
| Lumiflavin SCHEMBL6365933 | 0.78 | MEN1 (0.74) | GSRMAPTMEN1KMT2ATDP2 | |
| SCHEMBL24238131 | 0.77 | MEN1 (0.55) | GSRMAPTMEN1KMT2ATDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164483-B | Pharmaceutical composition for preventing or treating cancer containing PLK1 inhibitor as active ingredient | 国立癌症中心 | 2024-09-24 | — | — | CN | claimed |
| US-20230148252-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING A FLAVIN DERIVATIVE, A POLYMERIZABLE MOLECULE AND LIGHT RADIATION | L'OREAL (FR) | 2023-05-11 | — | — | US | claimed |
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | NATIONAL CANCER CENTER (KR) | 2022-02-03 | — | — | US | claimed |
| EP-3727318-B1 | PROCESS FOR TREATING KERATIN MATERIALS USING A FLAVIN DERIVATIVE, A POLYMERIZABLE MOLECULE AND LIGHT RADIATION | OREAL (FR) | 2022-01-19 | — | — | EP | claimed |
| US-20200375866-A1 | HAIR TREATMENT PROCESS USING A FLAVIN DERIVATIVE AND LIGHT RADIATION | L'OREAL (FR) | 2020-12-03 | — | — | US | claimed |
| WO-2020111325-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING ACTIVATION INHIBITOR OF PLK1 AS ACTIVE INGREDIENT | 국립암센터 | 2020-06-04 | — | — | WO | claimed |
| CN-113164483-B | Pharmaceutical composition for preventing or treating cancer containing PLK1 inhibitor as active ingredient | 国立癌症中心 | 2024-09-24 | — | — | CN | disclosed |
| US-20230148252-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING A FLAVIN DERIVATIVE, A POLYMERIZABLE MOLECULE AND LIGHT RADIATION | L'OREAL (FR) | 2023-05-11 | — | — | US | disclosed |
| US-20230148252-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING A FLAVIN DERIVATIVE, A POLYMERIZABLE MOLECULE AND LIGHT RADIATION | L'OREAL (FR) | 2023-05-11 | — | — | US | disclosed |
| US-20230148252-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING A FLAVIN DERIVATIVE, A POLYMERIZABLE MOLECULE AND LIGHT RADIATION | L'OREAL (FR) | 2023-05-11 | — | — | US | disclosed |
| EP-3492104-B1 | USE OF 10H-BENZO [G] PTERIDIN-2,4-DION DERIVATIVES | TRIOPTOTEC GMBH (DE) | 2023-02-15 | — | — | EP | disclosed |
| EP-3586632-B1 | 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR PRODUCING SAME AND USE OF SAME | TRIOPTOTEC GMBH (DE) | 2022-09-28 | — | — | EP | disclosed |
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | NATIONAL CANCER CENTER (KR) | 2022-02-03 | — | — | US | disclosed |
| US-8193430-B2 | Methods for separating carbon nanotubes | THE UNIVERSITY OF CONNECTICUT (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100044230-A1 | METHODS FOR SEPARATING CARBON NANOTUBES | UNIVERSITY OF CONNECTICUT (US) | 2010-02-25 | — | — | US | disclosed |
| EP-1297843-B1 | METHOD OF PHOTOREDUCTION OF HEMOGLOBIN VESICLES | UNIV WASEDA (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-6967020-B2 | Oxygen carrier system, artificial oxygen carrier, and reducing agent | OXYGENIX CO., LTD (JP) | 2005-11-22 | — | — | US | disclosed |
| US-6916303-B2 | Photoreduction method for hemoglobin-vesicle | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-07-12 | — | — | US | disclosed |
| EP-1297843-A1 | METHOD OF PHOTOREDUCTION OF HEMOGLOBIN VESICLES | Japan Science and Technology Corporation (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-20020095108-A1 | Photoreduction method for hemoglobin-visicle | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100044230-A1 | METHODS FOR SEPARATING CARBON NANOTUBES | FSCN1, TTPA, FLNB | GSR 366/4885MAPT 1575/4885MEN1 3231/4885 |
| US-20230148252-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING A FLAVIN DERIVATIVE, A POLYMERIZABLE MOLECULE AND LIGHT RADIATION | KRT18, FLNA, VIM | GSR 1584/4885MAPT 240/4885MEN1 3617/4885 |
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | PLK1, PLK2, PLK4 | GSR 4488/4885MAPT 919/4885MEN1 2253/4885 |
| US-20200375866-A1 | HAIR TREATMENT PROCESS USING A FLAVIN DERIVATIVE AND LIGHT RADIATION | FH, BLVRB, NQO1 | GSR 162/4885MAPT 757/4885MEN1 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.